Zymeworks (ZYME) Insider Trading & Ownership → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free ZYME Stock Alerts $8.55 -0.01 (-0.12%) (As of 04/24/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Zymeworks (NYSE:ZYME) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.22%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$27.20 MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$436,263.55 Get ZYME Insider Trade Alerts Want to know when executives and insiders are buying or selling Zymeworks stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ZYME Insider Buying and Selling by Quarter Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report Zymeworks Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/8/2024Christopher AstleCFOSell1,431$11.22$16,055.82 1/8/2024Kenneth GalbraithCEOSell5,706$11.22$64,021.32 1/8/2024Paul Andrew MooreInsiderSell2,339$11.22$26,243.58 1/5/2024Christopher AstleCFOSell4,563$10.65$48,595.95 1/5/2024Kenneth GalbraithCEOSell18,198$10.65$193,808.70 1/5/2024Paul Andrew MooreInsiderSell7,460$10.65$79,449.00 12/11/2023Christopher AstleCFOSell886$9.13$8,089.18 6/16/2023Ecor1 Capital, LlcMajor ShareholderBuy3,350,000$8.12$27,202,000.00 (Data available from 1/1/2013 forward) ZYME Insider Trading Activity - Frequently Asked Questions Who is on Zymeworks's Insider Roster? The list of insiders at Zymeworks includes Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson, and Paul Andrew Moore. Learn more on insiders at ZYME. What percentage of Zymeworks stock is owned by insiders? 1.22% of Zymeworks stock is owned by insiders. Learn more on ZYME's insider holdings. Which Zymeworks insiders have been buying company stock? The following insider purchased ZYME shares in the last 24 months: Ecor1 Capital, Llc ($44,875,510.00). How much insider buying is happening at Zymeworks? Insiders have purchased a total of 5,396,200 ZYME shares in the last 24 months for a total of $44,875,510.00 bought. Which Zymeworks insiders have been selling company stock? The following insiders have sold ZYME shares in the last 24 months: Christopher Astle ($78,071.82), Kenneth Galbraith ($257,830.02), Neil A Klompas ($23,309.91), Neil Josephson ($20,047.50), and Paul Andrew Moore ($105,692.58). How much insider selling is happening at Zymeworks? Insiders have sold a total of 46,922 Zymeworks shares in the last 24 months for a total of $484,951.83 sold. More Insider Trading Tools from MarketBeat Related Companies: ORIC Insider Selling LYEL Insider Selling WVE Insider Selling SIGA Insider Selling NUVB Insider Selling VERV Insider Selling MLYS Insider Selling PRAX Insider Selling AVTE Insider Selling SVRA Insider Selling Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Pagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1 This page (NYSE:ZYME) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupWill this $2 AI stock double overnight?Behind the MarketsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.